**Supplementary Table 1:** ECMO vs. No ECMO groupings via AKI presence or absence

|  |  |  |
| --- | --- | --- |
|  | **ECMO** | **No ECMO** |
| **AKI (n = 20)** | 12 (60%) | 8 (40%) |
| **No AKI (n = 34)** | 7 (21%) | 27 (79%) |

**Chi Squared: P = 0.003**

**Supplementary Table 2:** Vancomycin Toxicity in AKI vs. No AKI cohorts

|  |  |  |
| --- | --- | --- |
|  | **AKI (n = 20)** | **No AKI (n = 24)** |
| **Vancomycin Toxicity** | 19 (95%) | 13 (54%) |
| **No Vancomycin Toxicity** | 1 (5%) | 11 (46%) |

**Chi Squared: P = 0.003**